Legal & General Group
NDRM

Legal & General Group’s NeuroDerm Ltd. Ordinary Shares NDRM Stock Holding History

Legal & General Group’s Portfolio NDRM Stock Details NDRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-460
Closed -$18K – 3337
2017
Q3 		$18K Buy
460
+150
+48% +$5.52K ﹤0.01% 3202
2017
Q2 		$9K Sell
310
-230
-43% -$5.96K ﹤0.01% 3329
2017
Q1 		$14K Buy
+540
New +$13.4K ﹤0.01% 3158

Other funds holding NDRM

VOAM
Vertex One Asset Management Vancouver, British Columbia, Canada $434M AUM 37.82% 1-Year Est. Return
OTC
Opera Trading Capital Paris, France $419M AUM 0.58% 1-Year Est. Return
IA
IFP Advisors Tampa, Florida $5.54B AUM 27.43% 1-Year Est. Return
FWM
Focused Wealth Management Newburgh, New York $964M AUM 18.71% 1-Year Est. Return

Legal & General Group's NDRM Position: Q4 2017 in Review

Legal & General Group sold out of NeuroDerm Ltd. Ordinary Shares (NDRM) in Q4 2017, closing a stake of 460 shares — an estimated $18K sold.

Legal & General Group first reported a position in NDRM in Q1 2017 and held it in 3 quarters. The position peaked at $18K in Q3 2017. 5 funds tracked by Wall St. Rank hold NDRM as of Q4 2017.

  • Legal & General Group reported no remaining NeuroDerm Ltd. Ordinary Shares position as of Q4 2017 after selling out during the quarter.
  • Legal & General Group sold 460 NeuroDerm Ltd. Ordinary Shares shares in Q4 2017, an estimated $18K.
  • Legal & General Group first reported a position in NeuroDerm Ltd. Ordinary Shares in Q1 2017 and held it in 3 quarters.
  • Legal & General Group's NeuroDerm Ltd. Ordinary Shares position peaked at $18K in Q3 2017.
  • 5 funds tracked by Wall St. Rank held NeuroDerm Ltd. Ordinary Shares as of Q4 2017.

Based on Legal & General Group's 13F filing for Q4 2017, filed 13 Feb 2018.